Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics cash
Cash and short-term investments held at the end of each period.
Kymera Therapeutics's cash was $971.21M at Sep 30, 2026. For fiscal 2025 it was $848.28M, up 73.6% from the year before. The highest annual figure on record is $848.28M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $848.28M | +73.6% |
| FY2024 | Dec 31, 2024 | $488.74M | +30.4% |
| FY2023 | Dec 31, 2023 | $374.88M | -7.9% |
| FY2022 | Dec 31, 2022 | $407.17M | -8.0% |
| FY2021 | Dec 31, 2021 | $442.42M | +49.4% |
| FY2020 | Dec 31, 2020 | $296.20M | +222.1% |
| FY2019 | Dec 31, 2019 | $91.96M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $971.21M | +92.1% |
| Q2 FY2026 | Jun 30, 2026 | $690.99M | +3.8% |
| Q1 FY2026 | Mar 31, 2026 | $650.93M | +40.5% |
| Q4 FY2025 | Dec 31, 2025 | $848.28M | +73.6% |
| Q3 FY2025 | Sep 30, 2025 | $505.68M | -8.1% |
| Q2 FY2025 | Jun 30, 2025 | $665.45M | +30.5% |
| Q1 FY2025 | Mar 31, 2025 | $463.15M | -11.0% |
| Q4 FY2024 | Dec 31, 2024 | $488.74M | +30.4% |
| Q3 FY2024 | Sep 30, 2024 | $549.97M | +53.7% |
| Q2 FY2024 | Jun 30, 2024 | $509.95M | +38.7% |
| Q1 FY2024 | Mar 31, 2024 | $520.54M | +31.2% |
| Q4 FY2023 | Dec 31, 2023 | $374.88M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $357.83M | -25.7% |
| Q2 FY2023 | Jun 30, 2023 | $367.57M | -6.3% |
| Q1 FY2023 | Mar 31, 2023 | $396.88M | -5.7% |
| Q4 FY2022 | Dec 31, 2022 | $407.17M | -8.0% |
| Q3 FY2022 | Sep 30, 2022 | $481.91M | -10.2% |
| Q2 FY2022 | Jun 30, 2022 | $392.31M | +9.2% |
| Q1 FY2022 | Mar 31, 2022 | $420.81M | +26.2% |
| Q4 FY2021 | Dec 31, 2021 | $442.42M | +49.4% |
| Q3 FY2021 | Sep 30, 2021 | $536.39M | +82.5% |
| Q2 FY2021 | Jun 30, 2021 | $359.11M | +489.0% |
| Q1 FY2021 | Mar 31, 2021 | $333.54M | +175.1% |
| Q4 FY2020 | Dec 31, 2020 | $296.20M | +222.1% |
| Q3 FY2020 | Sep 30, 2020 | $293.84M | +5403.7% |
| Q2 FY2020 | Jun 30, 2020 | $60.97M | – |
| Q1 FY2020 | Mar 31, 2020 | $121.25M | – |
| Q4 FY2019 | Dec 31, 2019 | $91.96M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.34M | – |
See a number that looks wrong?